Fedratinib

5 trials 1 recruiting LOncology Orphan designation

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

1 Recruiting

4 Completed trials

5 Sponsors

12 Countries

Phase III

Phase II

Phase I/II

Phase III: 1 Phase II: 1 Phase I/II: 3

Indications tested

Myelofibrosis 3

Sponsors using this IMP

Bristol-Myers Squibb Services Unlimited Company 1 Celgene Corp. 1 Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH 1 iOnctura SA 1 Martin-Luther-Universitaet Halle-Wittenberg 1

All trials

5 total

A Phase I/II with Ruxolitinib in Patients with Myelofibrosis (MF) who are Unresponsive to JAK inhibitors (HEMA-MED) Recruiting

2024-515252-20-00 Phase I/II 2 countries iOnctura SA
A Phase 1b/2 Study of BMS-986158 Monotherapy and Combination with either Ruxolitinib or Fedratinib in Intermediate or High Risk Myelofibrosi… Ended

2023-509635-89-00 Phase I/II 7 countries Bristol-Myers Squibb Services Unlimited Company
Study to evaluate the efficacy and safety of fedratinib in combination with CC-486 in patients suffering from myelofibrosis in acute phase. Ended

2024-519227-22-00 Phase I/II 1 country Martin-Luther-Universitaet Halle-Wittenberg
Phase II Study of Fedratinib and Nivolumab Combination in Patients with Myelofibrosis and Resistance or Suboptimal Response to JAK-inhibitor… Ended

2024-513953-64-00 Phase II 1 country Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
A study comparing current standard therapies with fedratinib for the treatment of myelofibrosis (either diagnosed alone or after polycythemi… Ended

2024-511972-33-00 Phase III 10 countries Celgene Corp.

Showing 1–5 of 5 trials

← All drugs A–Z